X0202 SCHEDULE 13D/A 1376474-25-000302 0001671957 XXXXXXXX LIVE 3 Common Stock 03/17/2025 false 0001997403 00098936T ZenaTech, Inc.

777 HORNBY STREET, SUITE 1460 VANCOUVER A1 V6Z 1S4

Dr. Shaun Passley (647) 249-1622 777 Hornby Street, Suite 1460 Vancouver A1 V6Z 1S4 0001671957 Dr. Shaun Passley OO X1 58028205 287828839 58028205 287828839 287828839 86.5 IN Comprised of (i) 7,668,205 common shares, 5,120,000 preferred shares and 35,000 super-voting shares held by Dr. Passley, (ii) 10,867,301 common shares, 21,700,000 preferred shares and 145,000 super-voting shares held by Epazz, Inc. ("Epazz"), and (iii) 1,583,333 common shares, 750,000 preferred shares and 5,000 super-voting shares held by Ameritek Ventures Inc. ("Ameritek"). Each preferred share is convertible into three common shares. Each super-voting share carries 1,000 votes per share. The aggregate number of votes available at the Company, assuming the conversion of all preferred shares to common shares and the exercise of voting rights attached to such common shares and the exercise of voting rights attached to all super-voting shares, is 332,699,794. Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz, Inc. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek. 0001335239 Epazz Inc OO WY 0 220967301 0 220967301 220967301 66.4 CO Comprised of 10,867,301 common shares, 21,700,000 preferred shares and 145,000 super-voting shares held by Epazz. Each preferred share is convertible into three common shares. Each super-voting share carries 1,000 votes per share. The aggregate number of votes available at the Company, assuming the conversion of all preferred shares to common shares and the exercise of voting rights attached to such common shares and the exercise of voting rights attached to all super-voting shares, is 332,699,794. Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz, Inc. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek. 0001530185 Ameritek Ventures, Inc. OO NV 0 8333333 0 8333333 8333333 2.5 CO Comprised of 1,583,333 common shares, 750,000 preferred shares and 5,000 super-voting shares held by Ameritek. Each preferred share is convertible into three common shares. Each super-voting share carries 1,000 votes per share. The aggregate number of votes available at the Company, assuming the conversion of all preferred shares to common shares and the exercise of voting rights attached to such common shares and the exercise of voting rights attached to all super-voting shares, is 332,699,794. Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz, Inc. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek. Common Stock ZenaTech, Inc. 777 HORNBY STREET, SUITE 1460 VANCOUVER A1 V6Z 1S4 This Schedule 13D relates to the common shares, preferred shares and super-voting shares of ZenaTech Inc., a British Columbia, Canada corporation (the "Issuer"). The principal executive offices of the Issuer are located at Suite 1460, 777 Hornby Street, Vancouver, British Columbia V6Z 1S4 Canada. Shaun Passley 777 Hornby Street, Suite 1460 Vancouver, British Columbia Canada V6Z 1S4 This statement on Schedule 13D is filed on behalf of Epazz, Inc. (Epazz) and Dr. Shaun Passley (collectively the Reporting Persons) subsequent to shareholder approval of (i) the issuance of equity grants to Dr. Passley under a new employment agreement between the Company and Dr. Passley (the New CEO Agreement) and (ii) the acquisition by the Company of certain assets from Epazz, as described in the Information Circular (the Information Circular) relating to the Special Meeting of Shareholders (the Special Meeting) of the Company held on January 30, 2026 (a copy of which was filed by the Company with the SEC under cover of Form 6-K dated January 12, 2026). Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz. Dr. Passley is also the sole director, officer, and principal shareholder of Ameritek, as Epazz is the principal shareholder of Ameritek with 95% voting control of Ameritek. Epazz is organized under the laws of the State of Wyoming and its business address is 55 E. Jackson Blvd. Chicago, IL 60604. Epazz is in the business of developing technology. Dr. Passley is a USA citizen and is the sole director and officer of Epazz. Dr. Passley's principal occupation is the CEO of the Issuer. During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the past five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. N/A U.S.A. Dr. Passley was issued super-voting shares and preferred shares by the Company pursuant to the New CEO Employment Agreement subsequent to receiving shareholder approval for the grants at the Special Meeting. Epazz was issued super-voting shares and preferred shares subsequent to receiving shareholder approval for the acquisition by the Company of certain assets from Epazz at the Special Meeting. See the Information Circular and Section 5(c) below for more information. The Reporting Persons acquired the Issuer's common stock for investment purposes. None of the Reporting Persons have any plans or proposals which relate to or would result in any of the matters listed in Items 4(a) to 4(j) of Schedule 13D. The beneficial holdings of Epazz, Ameritek and Dr. Passley in the Company are set forth in Exhibit B hereto. Dr. Passley is the sole director and officer of Epazz, and is its principal shareholder with 95% voting control of Epazz. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek. As described in the Information Circular, at the Company's Special Meeting held January 30, 2026, the shareholders of the Company approved (i) the issuance of equity grants to Dr. Passley pursuant to the New CEO Agreement and (ii) the acquisition by the Company of certain assets from Epazz. In consideration for the assets acquired, the Company issued super-voting shares and preferred shares to Dr. Passley and Epazz. See Exhibit B hereto. See Exhibit B. Not applicable. None. Exhibit A: Joint Filing Agreement. Exhibit B: List of Shareholders. Dr. Shaun Passley Shaun Passley 04/02/2026 Epazz Inc Shaun Passley 04/02/2026 Ameritek Ventures, Inc. Shaun Passley 04/02/2026